Norges Bank Sigilon Therapeutics, Inc. Transaction History

Norges Bank

  • $716 Trillion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 07, 2021
SELL
$18.76 - $40.91 $140,700 - $306,825
-7,500 Closed
0 $0
Q4 2020

Mar 02, 2021
BUY
$27.6 - $48.03 $207,000 - $360,225
7,500 New
7,500 $360,000

About Sigilon Therapeutics, Inc.

SGTX Quotes by TradingView
  • Ticker SGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,399,300
  • Description
  • Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...
More about SGTX
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email